KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biocryst Pharmaceuticals (BCRX) Leases (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Leases for 3 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 6.36% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Dec 2025, down 6.36%, and an annual FY2025 reading of $7.5 million, down 6.36% over the prior year.
  • Leases was $7.5 million for Q4 2025 at Biocryst Pharmaceuticals, down from $7.7 million in the prior quarter.
  • Across five years, Leases topped out at $11.4 million in Q3 2023 and bottomed at $3.6 million in Q2 2025.
  • Average Leases over 3 years is $6.4 million, with a median of $7.0 million recorded in 2023.
  • The sharpest move saw Leases tumbled 65.97% in 2024, then surged 99.46% in 2025.
  • Year by year, Leases stood at $8.7 million in 2023, then decreased by 7.15% to $8.1 million in 2024, then decreased by 6.36% to $7.5 million in 2025.
  • Business Quant data shows Leases for BCRX at $7.5 million in Q4 2025, $7.7 million in Q3 2025, and $3.6 million in Q2 2025.